Introduction {#ss1}
============

Studies have been designed to use exhaled NO to target the treatment of asthma, and recently a Cochrane review has concluded that, at present, defining the dose of inhaled corticosteroids based on exhaled NO cannot be routinely advocated ([@CIT0001]). It has also been concluded in an American Thoracic Society/European Respiratory Society (ATS/ERS) document on standardizing end-points for clinical asthma trials and clinical practice that in clinically stable asthma the exhaled NO (F~E~NO) values are generally higher than in healthy control subjects ([@CIT0002]). Therefore, reference NO values are of limited use in guiding the clinician in the treatment of patients with asthma. In the present case study it is demonstrated why the F~E~NO~0.05~ (fractional concentration of exhaled NO in the gas phase, 0.05 L/s) remains high after treatment and that NO parameters from non-linear modelling are clinically useful.

Case study {#ss2}
==========

A male subject, 30 years of age, with the diagnosis of atopic asthma since childhood was investigated. The baseline NO analysis was done without inhaled corticosteroids (ICS). After one week on 800 microgram ICS twice a day, F~E~NO values were obtained again with multiple flow rates using a CLD 88sp NO analyser (ECO Medics AG, Switzerland). The NO production of the respiratory system was computed with the non-linear NO model by Högman and Meriläinen ([@CIT0003]).

There was a dramatic decrease in F~E~NO~0.05~ of 58% in 1 week of treatment, but it was still higher than reference values for healthy controls ([@CIT0004]). In [Figure 1](#F1){ref-type="fig"} it can be seen that there was no change in airway diffusion capacity of NO (D~aw~NO) due to ICS. D~aw~NO is known to be increased in atopic rhinitis and atopic asthma ([@CIT0005]) and not affected by ICS ([@CIT0006]). The alveolar NO levels (C~A~NO) were low. Noteworthily, the airway tissue content (C~aw~NO) was reduced by ICS to levels presented for healthy controls ([@CIT0004]).

![F~E~NO~0.05~ and NO parameters, airway tissue concentration of NO (C~aw~NO), airway diffusion capacity for NO (D~aw~NO), and alveolar levels of NO (C~A~NO) in a case of allergic asthma. Values are given before and after 1 week of inhaled corticosteroids. Reference values for healthy controls are marked with a broken line (Högman et al. ([@CIT0004])). Note the decline in C~aw~NO to reference values while F~E~NO~0.05~ remained high.](UPS-118-59-f001){#F1}

Theoretical example {#ss3}
===================

When the NO parameters are known, the non-linear model can be used to calculate the F~E~NO~0.05~ ([@CIT0003]). Different values of C~aw~NO, D~aw~NO, and C~A~NO can be fed into a Microsoft Office Excel spreadsheet, where NO volumes at different expiratory flow rates are visualized and F~E~NO for specific flow rates are given. For the illustration, typical NO values in health, atopy, and asthma are shown in [Table I](#T1){ref-type="table"}. Since D~aw~NO is not affected by ICS, this value can be used in the calculations together with C~aw~NO and C~A~NO values for healthy controls ([@CIT0003]). This calculation will result in a personal best or target value of F~E~NO~0.05~ to be used during treatment. This target value of F~E~NO~0.05~ was quite similar to the value after 1 week of treatment in this case study and in a group of asthmatics in a study by Silkoff et al. ([@CIT0006]).

###### 

C~A~NO, C~aw~NO, D~aw~NO, and F~E~NO~0.05~ values in health, atopy, and asthma. During steroid treatment, the target value of F~E~NO~0.05~ can be calculated when the D~aw~NO is known.

  Theoretical example                    C~A~NO (ppb)   C~aw~NO (ppb)   D~aw~NO (mL/s)   F~E~NO~0.05~ (ppb)   Ref.
  -------------------------------------- -------------- --------------- ---------------- -------------------- ---------------------------
  Healthy subject                        1              106             8                16                   ([@CIT0004])
  Atopic rhinitis                        1              106             12               23                   ([@CIT0005])
  * Target F~E~NO~0.05~*                                                                 *23*                 
  Atopic asthma                                                                                               
  * *Before steroids                     1              266             18               82                   This case report
  * *After steroids                      1              102             20               34                   
  * Target F~E~NO~0.05~*                                                                 *33*                 
  Asthma                                                                                                      
  * *At 6 weeks withdrawal of steroids   3              255             25               102                  Adopted from ([@CIT0006])
  * *After steroids                      3              108             22               40                   
  * Target F~E~NO~0.05~*                                                                 *42*                 

C~A~NO = calculated fractional concentration of NO in the gas phase of the alveolar region; C~aw~NO = calculated tissue concentration of NO of the airway wall; D~aw~NO = calculated airway compartment diffusing-capacity from the airway wall to the gas stream; F~E~NO~0.05~ = fractional concentration of exhaled NO in the gas phase 0.05 L/s.

Discussion {#ss4}
==========

One week of ICS reduced the C~aw~NO to reference levels for healthy controls. The F~E~NO~0.05~ level stayed elevated, which is due to the lack of change in D~aw~NO, known to be high in allergic asthma ([@CIT0005]) and not affected by ICS in asthma ([@CIT0006]).

In a study by Smith et al. ([@CIT0007]) it was concluded that optimum F~E~NO levels were best established by using oral rather than inhaled steroid treatment and that values were higher than reference values even though asthma was well controlled. The finding in this case study gives other solutions to finding the personal best value of F~E~NO~0.05~. One solution is to use the non-linear NO model and follow the ICS treatment with C~aw~NO. Another solution is to determine the D~aw~NO for the patient and then use the C~aw~NO and C~A~NO for healthy controls to identify a target value of F~E~NO~0.05~. In our patient it was 33 ppb. The F~E~NO value can then be followed with a simple portable NO device in primary care.

The importance of controlling F~E~NO has been shown in children, where airway hyper-responsiveness improved with lower F~E~NO ([@CIT0008]), and in difficult-to-treat asthma, where an increased NO value was a predictor of accelerated decline in lung function ([@CIT0009]). Therefore NO values should preferentially be monitored in allergic asthma in both children and adults, and D~aw~NO is useful for targeting F~E~NO~0.05~. Further studies have to be designed to evaluate the personal best NO value by an approach presented in this case report.
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